CLIA Kit for Myostatin (MSTN) Homo sapiens (Human) Sandwich CLIA

GDF8; Growth Differentiation Factor 8

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Myostatin (MSTN) Packages (Simulation)
  • CLIA Kit for Myostatin (MSTN) Packages (Simulation)
  • CLIA Kit for Myostatin (MSTN) Results demonstration
  • SCB653Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Myostatin (MSTN) and the recovery rates were calculated by comparing the measured value to the expected amount of Myostatin (MSTN) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 93-101 97
EDTA plasma(n=5) 79-101 93
heparin plasma(n=5) 87-102 98

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Myostatin (MSTN) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Myostatin (MSTN) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Myostatin (MSTN) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-88% 88-95% 91-101% 85-105%
EDTA plasma(n=5) 92-99% 88-96% 79-97% 97-105%
heparin plasma(n=5) 97-104% 78-96% 81-97% 95-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Myostatin (MSTN)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Myostatin (MSTN). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Myostatin (MSTN). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Myostatin (MSTN) level in the sample or standard.;

Citations

  • Anti-Myostatin Reduces Bone Mineral Loss in Ovariectomized RatsSapub:Source
  • Short-term, high-fat diet accelerates disuse atrophy and protein degradation in a muscle-specific manner in micePubMed: 26539241
  • Tumor inoculation site affects the development of cancer cachexia and muscle wastingPubMed: 26016447
  • Induction of transient tenogenic phenotype of high density cultured human dermal fibroblastsPubMed: 25748814
  • Higher Plasma Myostatin Levels in Cor Pulmonale Secondary to Chronic Obstructive Pulmonary DiseasePubmed:26998756
  • The Effect of Vibration Treatments Combined with Teriparatide or Strontium Ranelate on Bone Healing and Muscle in Ovariectomized RatsPubmed:27272029
  • Irisin and Myostatin Levels in Patients with Graves' Disease.pubmed:27986127
  • Effect of Strontium Ranelate on the Muscle and Vertebrae of Ovariectomized Ratspubmed:29242963
  • Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis.pubmed:28740214
  • Fermented corn-soybean meal elevated IGF1 levels in grower-finisher pigsPubmed: 30203098
  • Predictive value of serum myostatin for the severity and clinical outcome of heart failurePubmed: 31056368
  • Resistance training‐induced muscle hypertrophy is mediated by TGF‐β1‐Smad signaling pathway in male Wistar ratsPubmed: 31960436
  • Myostatin and muscle atrophy during chronic kidney diseasePubmed: 32974666
  • Gender-Specific Behaviour in Obesity Stages I-II: Imbalance of Aminothiol Status and Adipomyokine Profile in Subjects with Different Insulin Resistance …34868459

Recommend products